Corrigendum to the summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 March 2012 to 31 March 2012 (Official Journal of the European Union C 124 of 27 April 2012) 2012/C 171/14
Grade B
mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.
Address https://gelex.eu/eli/EU/corrigendum/oj/C/2012/171/14@2012-06-16/en
On page 3, in the table, after the entry for NutropinAq, the following row is inserted: 2.3.2012 Omnitrope Sandoz GmbH Biochemiestrasse 10, Kundl 6250, Österreich EU/1/06/332/001-012 6.3.2012
—
on page 9, the following is deleted: Suspension of a marketing authorization (Article 20 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) Date of the decision Name of the medicinal product Holder of the marketing authorization Number of the entry in the Community Register Date of notification 2.3.2012 Omnitrope Sandoz GmbH Biochemiestrasse 10, Kundl 6250, Österreich EU/1/06/332/001-012 6.3.2012